Following a series of laboratory experiments in mice and in human immune cells, the research team discovered the major difference between HA-MRSA and its less deadly cousin, community-acquired MRSA, comes down to whether a set of dueling toxins are present or absent.
The study specifically found that LUK-PV, a bacterial poison secreted only by CA-MRSA, counteracts the effects of another more deadly toxin called LUK-ED, which is secreted by both forms of the MRSA bacterium.
“Essentially, in community-acquired MRSA, the toxins neutralize each other, while in the hospital superbug form, they do not,” explained Victor Torres, PhD, the study’s senior investigator and an NYU Langone microbiologist.
According to Dr. Torres, the results of the study challenge the current mindset for finding a vaccine against staphylococcal infections and, in doing so, pave the way to develop an effective vaccine.
More articles on MRSA:
MRSA infections become increasingly common among school-aged children
25 things for healthcare CFOs to know about HAIs
Which 9 hospitals reported zero C. diff and MRSA infections?
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.